Details of the Drug Combinations

General Information of This Drug (ID: DM2BLMT)

Drug Name

ABT-199 DM2BLMT

Indication

Disease Entry	ICD 11	Status	REF
Chronic lymphocytic leukaemia	2A82.0	Phase 3	[1]
------------------------------------------------------------------------------------

List of Combinatorial Drugs (CBD) Containing This Drug

9 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
ABT-199 + Ruxolitinib	DCYM8AB	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[2]
ABT-199 + JQ1	DC65KCR	JQ1	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
ABT-199 + Carfilzomib	DC6JUCQ	Carfilzomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
ABT-199 + Panobinostat	DCZRQV1	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
ABT-199 + Abexinostat	DCIZZQS	Abexinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
ABT-199 + SNDX-275	DCI7C9Q	SNDX-275	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
ABT-199 + Resminostat	DCWQUUE	Resminostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
ABT-199 + CF102	DCCFSG1	CF102	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
ABT-199 + THZ1	DC4BWMZ	THZ1	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 DrugCom(s)

References

1	Clinical pipeline report, company report or official report of Abbott Laboratories.
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.